Actionable news
0
All posts from Actionable news
Actionable news in BLUE: bluebird bio, Inc.,

bluebird bio Announces Participation in 24th Annual Credit Suisse Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies, today announced that members of the management team will participate in the 24th Annual Credit Suisse Healthcare conference on Tuesday, November 10th with a fireside chat at 8:30 a.m. MT/10:30 a.m. ET. The conference is being held at the Phoenician Hotel in Scottsdale, Arizona.

To access the live webcast of bluebird bio’s fireside chat, please visit the “Calendar of Events” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcast will be available on the bluebird bio website for 90 days following the conference.

About bluebird bio, Inc.

With its lentiviral-based gene therapy and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and T cell-based immunotherapy. bluebird bio’s clinical programs include Lenti-D™, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of childhood cerebral adrenoleukodystrophy, and...


More